表紙
市場調査レポート

Pristiq(大鬱病性障害)- 予測と市場分析

Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 305478
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
Pristiq(大鬱病性障害)- 予測と市場分析 Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023
出版日: 2014年05月30日 ページ情報: 英文 45 Pages
概要

大鬱病性障害(MDD)は、世界で最も一般的な精神疾患の1つです。MDD市場は競争が激しく、30以上もの上市製品がMDD患者の治療に使用可能です。鬱病市場では、主力製品(Eli LillyのCymbalta、大塚製薬/BMSのAbilify)の特許切れが差し迫り、抗鬱薬の新製品(Lundbeck/武田薬品工業のBrintellix)や将来有望な後期段階のパイプライン製品の導入を目前に、市場は大きく動いています。

当レポートでは、MDDの治療薬であるPristiqについて調査分析し、疾病の概要と治療ガイドライン、競合情勢、製品情報、売上予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 分類
  • 症状とサブタイプ
  • 予後
  • QOL

第4章 疾病の管理

  • 診断と治療の概要

第5章 競合評価

  • 概要

第6章 Pristiq(Desvenlafaxine)

  • 概要
  • 効能
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表

目次
Product Code: GDHC419DFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Pristiq (desvenlafaxine) is an SNRI antidepressant that was developed by Wyeth, before Wyeth was acquired by Pfizer. Pristiq was launched in the US and Australia in 2008, but is not available in the 5EU and Japan. Pristiq is closely related to Effexor, and more specifically, is the major active metabolite of Effexor. Therefore, despite being a newer SNRI antidepressant, Pristiq will be unable to match the success of Cymbalta and Effexor. Preclinical studies have shown that Pristiq is a potent SNRI, which is believed to cause its antidepressant effects.

Scope

  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Pristiq including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Pristiq for the top three countries from 2013 to 2023.
  • Sales information covered for the US, Spain and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Pristiq performance
  • Obtain sales forecast for Pristiq from 2013-2023 in the top three countries (the US, Spain and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms and Subtypes of Major Depressive Disorder
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Pristiq (Desvenlafaxine)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed MDD Patients
    • 7.4.2. Percent of Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. About the Authors
    • 7.6.1. Analyst
    • 7.6.2. Therapy Area Directors
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10)
  • Table 2: Subtypes of Major Depressive Disorder
  • Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria
  • Table 4: Treatment Guidelines for Major Depressive Disorder
  • Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013
  • Table 6: Leading Treatments for MDD, 2013
  • Table 7: Product Profile - Pristiq
  • Table 8: Efficacy of Pristiq in short-term studies
  • Table 9: Pristiq SWOT Analysis, 2014
  • Table 10: Global MDD Sales Forecasts ($m) for Pristiq, 2013-2023
  • Table 11: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
  • Figure 2: Disease Management Model for Major Depressive Disorder
  • Figure 3: Major Depressive Disorder Treatment Algorithm
Back to Top